Gilead Sciences, Inc.
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), Gilead Sciences, Inc. reported 6 stock positions worth $1.9 billion. Its top holding was Arcus Biosciences (RCUS) at 38.7% of the portfolio, followed by Lakefront Biotherapeutic-ADR (LKFT, 28.4%) and Arcellx (ACLX, 22.6%). Compared with Q3 2025, it sold out of 3. The biggest sale was an exit from Merus (MRUS).
- Most Recent 13F
- Q2 2026
- Location
- FOSTER CITY, CA
- CIK
- 0000882095
- Portfolio Value
- $1.9B (Q4 2025)
- SEC Filing
- 0001123292-26-000164 ↗ filed Feb 12, 2026
Holdings Value
Holdings 6 stocks · $1.9B
| RCUS Arcus Biosciences Inc. | 38.69% | 31,424,760 | $748.9M | No change |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 28.45% | 16,707,477 | $550.6M | No change |
| ACLX Arcellx Inc. | 22.64% | 6,720,803 | $438.2M | No change |
| ASMB Assembly Biosciences Inc. | 7.92% | 4,505,391 | $153.2M | No change |
| KYTX Kyverna Therapeutics Inc. | 2.00% | 4,126,119 | $38.8M | No change |
| XLO Xilio Therapeutics Inc. | 0.30% | 9,105,451 | $5.8M | No change |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $1.6B | RCUS, LKFT, ASMB, KYTX, XLO |
| Q1 2026 | 6 | $2.1B | ACLX, RCUS, LKFT, ASMB, KYTX |
| Q4 2025 | 6 | $1.9B | RCUS, LKFT, ACLX, ASMB, KYTX |
| Q3 2025 | 9 | $1.8B | LKFT, ACLX, RCUS, ASMB, MRUS |
| Q2 2025 | 14 | $1.3B | LKFT, ACLX, RCUS, ASMB, TNGX |
| Q1 2025 | 14 | $1.2B | ACLX, LKFT, RCUS, ASMB, MRUS |
| Q4 2024 | 16 | $1.6B | ACLX, LKFT, RCUS, ASMB, MRUS |